Our Team

The following members of the executive team are the original founders of Breath Diagnostics and each has been instrumental in the design and testing of the technologies and application of OneBreath™.

Michael Bousamra's Picture Michael Bousamra II, MD

Dr. Bousamra is a co-founder and the president of Breath Diagnostics. He is responsible for developing the idea of breath analysis for lung cancer detection. Dr. Bousamra is an Associate Professor of Cardiovascular and Thoracic Surgery at the University of Louisville School of Medicine.

Past professional appointments include President of the Jewish Hospital Medical Staff in addition to service on numerous advisory, steering and hospital administrative committees, notably the Executive Committee at JHSMH, the Operating Committee at Jewish Hospital and a host of academic appointments. A prolific author and presenter, Dr. Bousamra holds patents on methods to detect cancer in animals and exhaled breath sampling method, device and analysis.

Michael Nantz's Picture Michael H. Nantz, Ph.D.

Dr. Nantz is a Co-Founder of Breath Diagnostics. He was instrumental in designing aminooxy compound ATM, a critical component of the microreactor used to capture the volatile organic compounds found in lung cancers. Dr. Nantz earned his Ph.D. in 1987 from Purdue University working in the field of natural product synthesis and he explored asymmetric synthesis as a postdoctoral researcher at M.I.T.

He came to the University of Louisville from the University of California, Davis where he focused on organic synthesis for seventeen years. During his career, and now as the Chairman of the Department of Chemistry at UofL, he mentored 25 Ph.D. graduates, published over 130 research articles, obtained 13 US patents, and co-authored two textbooks on organic chemistry.

Dr. Fu's Picture Dr. Xiao-An (Sean) Fu, Ph.D.

Dr. Fu, serves as vice president and is responsible for developing the microchip concentration device that is critical in the capture of the rare volatile organic compounds associated with cancer in breath. He is an Associate Professor of Chemical Engineering at the University of Louisville.

Before joining the faculty of the University of Louisville in 2008 he was a researcher in the Department of Electrical Engineering and Computer Science at Case Western Reserve University. He invented a process for deposition of low stress polycrystalline SiC suitable as MEMS structure materials. Among his many research interests is breath analysis for the development of a noninvasive diagnostic tool for detection of early lung cancer, trace gas detection, active tuberculosis and other pulmonary diseases.

Victor van Berkel's Picture Victor van Berkel, MD, Ph.D.

Dr. van Berkel is the secretary of Breath Diagnostics and is responsible for clinical trial data coordination along with the recruitment of breath analysis patients and controls for studies. Dr. van Berkel is an Associate Professor of Surgery in the Department of Cardiovascular and Thoracic Surgery and the Director of the lung transplant program at the University of Louisville.

His clinical practice focuses on thoracic malignancies. After completing his undergraduate training at MIT, Dr. van Berkel earned both his MD and Ph.D. at Washington University in St. Louis prior to completing a fellowship in cardio-thoracic surgery. His general surgery residency was completed at Harvard Medical School. Dr. van Berkel is an active author and lecturer and his research interests include utilization of breath analysis to detect early stage lung cancer.

Rick Rummel's Picture Richard Rummel, CEO

Richard Rummel has been the CEO of Breath Diagnostics since April 2015. His experience includes over 28 years of medical device experience in device sales, new product development and multiple product launches. This is his fourth medical company startup with which he has worked.

He received his Bachelors in Science, Biology, from Hampden-Sydney College, Hampden-Sydney, Virginia, May 1982. He began his career in the medical device industry with Johnson & Johnson in 1988 for nine years prior to working with Elekta, Inc. He started his first company in 1998. Richard is a specialist in strategic market analysis and market development with particular emphasis in changes resulting from the Affordable Care Act.

Published Articles

Read about the newest developments and research in this technology.

Latest News

Connect with us on LinkedIn, Facebook and Twitter. We will include the latest news about our company.